Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals (REGN) based on the company’s closing price on March 27. Analysts have revised the company’s target price upward twice, from $417.27 in January to $428.86 in February and then to $430.24 in March.
The current consensus analyst recommendation on the stock is a “buy.”
Of the 23 analysts covering Regeneron Pharmaceuticals, four have given it “strong buys,” five have given it “buys,” 13 have given it “holds,” and one has given it a “sell.” The highest and lowest target price estimates for the company are $497 and $325, respectively.
On March 27, Regeneron Pharmaceuticals closed at $402.87, 0.68% lower than its previous closing price, 42.92% higher than its 52-week low of $281.89, and 8.86% lower than its 52-week high of $442. The company’s market cap is $44.44 billion.
Based on its closing price on March 27, Regeneron Pharmaceuticals has reported returns of -0.65% in the last week, -5.46% in the last month, and 18.27% in the last quarter. The company has reported returns of 3.25% in the last half year, 21.82% in the last year, and 7.86% year-to-date.
In its fourth quarter, Regeneron Pharmaceuticals reported revenue of $1.93 billion, a YoY (year-over-year) rise of 21.82% and $199.05 million higher than the consensus estimate. The company reported non-generally accepted accounting principles EPS of $6.84, a YoY rise of 30.78% and $1.24 higher than the consensus estimate.
On February 9, Regeneron Pharmaceuticals issued a press release announcing positive results from its Phase 3 PANORAMA trial evaluating the efficacy of early intervention with Eylea therapy in moderate to severe NPDR (non-proliferative diabetic retinopathy) indications. According to the press release, the FDA has set a target action date of May 13, 2019, for the supplemental biologics license application seeking approval for Eylea in NPDR indications.
On February 11, Regeneron Pharmaceuticals issued a press release announcing a 60% lower list price for Praluent in the United States, improving the chances of securing coverage for the drug.
However, on February 25, the company issued a press release announcing Regeneron Pharmaceuticals’ and Sanofi’s (SNY) opposition to a jury’s verdict of upholding two of Amgen’s (AMGN) Repatha patents. Amgen claims that these patents have been infringed by Praluent.